A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254-Reference-Cited by-同舟云学术

A phase III study of anti-B4-blocked ricin as adjuvant therapy post-autologous bone marrow transplant: CALGB 9254

Published:2011-01-28 Issue:4 Volume:52 Page:587-596
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Furman Richard R.,Grossbard Michael L.,Johnson Jeffrey L.,Pecora Andrew L.,Cassileth Peter A.,Jung Sin-Ho,Peterson Bruce A.,Nadler Lee M.,Freedman Arnold,Bayer Ruthee-Lu,Bartlett Nancy L.,Hurd David D.,Cheson Bruce D.,For The Cancer Leukemia Group B And

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2010.543714

Reference29 articles.

1. New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.

2. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

4. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

5. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Characterization of MAP c21873-1 as a new counter-selectable marker for unmarked genetic modification of Pichia pastoris;Microbial Cell Factories;2024-08-08

2. Pharmacology to Practice;Precision Cancer Therapies vol 2 ‐ Immunologic Approaches for the Treatment of Lymphoid Malignancies ‐ From Concept to Practice;2024-02-21

3. Engineering of Ribosome-inactivating Proteins for Improving Pharmacological Properties;Toxins;2020-03-09

4. Ricin and Ricinus communis in pharmacology and toxicology-from ancient use and “Papyrus Ebers” to modern perspectives and “poisonous plant of the year 2018”;Naunyn-Schmiedeberg's Archives of Pharmacology;2019-07-29

5. The Use of Plant-Derived Ribosome Inactivating Proteins in Immunotoxin Development: Past, Present and Future Generations;TOXINS;2017